Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine
Published in: Annals of Nuclear Medicine 5/2024

11-03-2024 | Glioma | Original Article

Impact of [11C]methionine PET with Bayesian penalized likelihood reconstruction on glioma grades based on new WHO 2021 classification

Authors: Kei Wagatsuma, Kensuke Ikemoto, Motoki Inaji, Yuto Kamitaka, Shoko Hara, Kaoru Tamura, Kenta Miwa, Kaede Tsuzura, Taisei Tsuruki, Noriaki Miyaji, Kenji Ishibashi, Kenji Ishii

Published in: Annals of Nuclear Medicine | Issue 5/2024

Login to get access

Abstract

Objective

The uptake of [11C]methionine in positron emission tomography (PET) imaging overlapped in earlier images of tumors. Bayesian penalized likelihood (BPL) reconstruction increases the quantitative values of tumors compared with conventional ordered subset-expectation maximization (OSEM). The present study aimed to grade glioma malignancy based on the new WHO 2021 classification using [11C]methionine PET images reconstructed using BPL.

Methods

We categorized 32 gliomas in 28 patients as grades 2/3 (n = 15) and 4 (n = 17) based on the WHO 2021 classification. All [11C]methionine images were reconstructed using OSEM + time-of-flight (TOF) and BPL + TOF (β = 200). Maximum standardized uptake value (SUVmax) and tumor-to-normal tissue ratio (T/Nmax) were measured at each lesion.

Results

The mean SUVmax was 4.65 and 4.93 in grade 2/3 and 6.38 and 7.11 in grade 4, and the mean T/Nmax was 7.08 and 7.22 in grade 2/3 and 9.30 and 10.19 in grade 4 for OSEM and BPL, respectively. The BPL significantly increased these values in grade 4 gliomas. The area under the receiver operator characteristic (ROC) curve (AUC) for SUVmax was the highest (0.792) using BPL.

Conclusions

The BPL increased mean SUVmax and mean T/Nmax in lesions with higher contrast such as grade 4 glioma. The discrimination power between grades 2/3 and 4 in SUVmax was also increased using [11C]methionine PET images reconstructed with BPL.
Literature
1.
Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018. Neuro Oncol. 2021;23(12 Suppl 2):iii1–105.PubMedPubMedCentralCrossRef
2.
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–51.PubMedPubMedCentralCrossRef
3.
Torp SH, Solheim O, Skjulsvik AJ. The WHO 2021 classification of central nervous system tumours: a practical update on what neurosurgeons need to know-a minireview. Acta Neurochir (Wien). 2022;164(9):2453–64.PubMedCrossRef
4.
Whitfield BT, Huse JT. Classification of adult-type diffuse gliomas: Impact of the World Health Organization 2021 update. Brain Pathol. 2022;32(4): e13062.PubMedPubMedCentralCrossRef
5.
Heiss WD, Raab P, Lanfermann H. Multimodality assessment of brain tumors and tumor recurrence. J Nucl Med. 2011;52(10):1585–600.PubMedCrossRef
6.
Glaudemans AW, Enting RH, Heesters MA, Dierckx RA, van Rheenen RW, Walenkamp AM, et al. Value of 11C-methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol Imaging. 2013;40(4):615–35.PubMedCrossRef
7.
Falk Delgado A, Falk DA. Discrimination between primary low-grade and high-grade glioma with 11C-methionine PET: a bivariate diagnostic test accuracy meta-analysis. Br J Radiol. 2018;91(1082):20170426.PubMedPubMedCentralCrossRef
8.
Lopci E, Riva M, Olivari L, Raneri F, Soffietti R, Piccardo A, et al. Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma. Eur J Nucl Med Mol Imaging. 2017;44(7):1155–64.PubMedCrossRef
9.
Russo G, Stefano A, Alongi P, Comelli A, Catalfamo B, Mantarro C, et al. Feasibility on the use of radiomics features of 11[C]-MET PET/CT in central nervous system tumours: preliminary results on potential grading discrimination using a machine learning model. Curr Oncol. 2021;28(6):5318–31.PubMedPubMedCentralCrossRef
10.
Hatakeyama T, Kawai N, Nishiyama Y, Yamamoto Y, Sasakawa Y, Ichikawa T, et al. 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging. 2008;35(11):2009–17.PubMedCrossRef
11.
Moulin-Romsee G, D’Hondt E, de Groot T, Goffin J, Sciot R, Mortelmans L, et al. Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for 11C-methionine? Eur J Nucl Med Mol Imaging. 2007;34(12):2082–7.PubMedCrossRef
12.
Pauleit D, Stoffels G, Bachofner A, Floeth FW, Sabel M, Herzog H, et al. Comparison of 18F-FET and 18F-FDG PET in brain tumors. Nucl Med Biol. 2009;36(7):779–87.PubMedCrossRef
13.
Nakajo K, Uda T, Kawashima T, Terakawa Y, Ishibashi K, Tsuyuguchi N, et al. Diagnostic performance of [11C]Methionine positron emission tomography in newly diagnosed and untreated glioma based on the revised World Health Organization 2016 classification. World Neurosurg. 2021;148:e471–81.PubMedCrossRef
14.
Ahn S, Ross SG, Asma E, Miao J, Jin X, Cheng L, et al. Quantitative comparison of OSEM and penalized likelihood image reconstruction using relative difference penalties for clinical PET. Phys Med Biol. 2015;60(15):5733–51.PubMedCrossRef
15.
Murata T, Miwa K, Miyaji N, Wagatsuma K, Hasegawa T, Oda K, et al. Evaluation of spatial dependence of point spread function-based PET reconstruction using a traceable point-like 22Na source. EJNMMI Phys. 2016;3(1):26.PubMedPubMedCentralCrossRef
16.
Teoh EJ, McGowan DR, Macpherson RE, Bradley KM, Gleeson FV. Phantom and clinical evaluation of the bayesian penalized likelihood reconstruction algorithm Q.clear on an LYSO PET/CT system. J Nucl Med. 2015;56(9):1447–52.PubMedCrossRef
17.
Aide N, Lasnon C, Kesner A, Levin CS, Buvat I, Iagaru A, et al. New PET technologies - embracing progress and pushing the limits. Eur J Nucl Med Mol Imaging. 2021;48(9):2711–26.PubMedPubMedCentralCrossRef
18.
Aljared A, Alharbi AA, Huellner MW. BSREM reconstruction for improved detection of in-transit metastases with digital FDG-PET/CT in patients with malignant melanoma. Clin Nucl Med. 2018;43(5):370–1.PubMedCrossRef
19.
Miwa K, Wagatsuma K, Nemoto R, Masubuchi M, Kamitaka Y, Yamao T, et al. Detection of sub-centimeter lesions using digital TOF-PET/CT system combined with Bayesian penalized likelihood reconstruction algorithm. Ann Nucl Med. 2020;34(10):762–71.PubMedCrossRef
20.
Te Riet J, Rijnsdorp S, Roef MJ, Arends AJ. Evaluation of a Bayesian penalized likelihood reconstruction algorithm for low-count clinical 18F-FDG PET/CT. EJNMMI Phys. 2019;6(1):32.CrossRef
21.
Asma E, Ahn S, Ross SG, Chen A, Manjeshwar RM. Accurate and consistent lesion quantitation with clinically acceptable penalized likelihood images. IEEE Nucl Sci Sympos Med Imaging Conf Record. 2012;2012:4062–6.
22.
Miwa K, Yoshii T, Wagatsuma K, Nezu S, Kamitaka Y, Yamao T, et al. Impact of gamma factor in the penalty function of Bayesian penalized likelihood reconstruction (Q.Clear) to achieve high-resolution PET images. EJNMMI Phys. 2023;10(1):4.PubMedPubMedCentralCrossRef
23.
Reynes-Llompart G, Gamez-Cenzano C, Vercher-Conejero JL, Sabate-Llobera A, Calvo-Malvar N, Marti-Climent JM. Phantom, clinical, and texture indices evaluation and optimization of a penalized-likelihood image reconstruction method (Q.Clear) on a BGO PET/CT scanner. Med Phys. 2018;45(7):3214–22.PubMedCrossRef
24.
Teoh EJ, McGowan DR, Bradley KM, Belcher E, Black E, Gleeson FV. Novel penalised likelihood reconstruction of PET in the assessment of histologically verified small pulmonary nodules. Eur Radiol. 2016;26(2):576–84.PubMedCrossRef
25.
Bettinardi V, Presotto L, Rapisarda E, Picchio M, Gianolli L, Gilardi MC. Physical performance of the new hybrid PETCT Discovery-690. Med Phys. 2011;38(10):5394–411.PubMedCrossRef
26.
Wagatsuma K, Miwa K, Sakata M, Oda K, Ono H, Kameyama M, et al. Comparison between new-generation SiPM-based and conventional PMT-based TOF-PET/CT. Phys Med. 2017;42:203–10.PubMedCrossRef
27.
Ogishima T, Tamura K, Kobayashi D, Inaji M, Hayashi S, Tamura R, et al. ATRX status correlates with 11 C-methionine uptake in WHO grade II and III gliomas with IDH1 mutations. Brain Tumor Pathol. 2017;34(1):20–7.PubMedCrossRef
28.
Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol. 2015;129(1):133–46.PubMedCrossRef
29.
Ebiko Y, Tamura K, Hara S, Inaji M, Tanaka Y, Nariai T, et al. T2-FLAIR mismatch sign correlates with 11C-methionine uptake in lower-grade diffuse gliomas. J Neurooncol. 2023;164(1):257–65.PubMedCrossRef
30.
Hirata K, Kobayashi K, Wong KP, Manabe O, Surmak A, Tamaki N, et al. A semi-automated technique determining the liver standardized uptake value reference for tumor delineation in FDG PET-CT. PLoS ONE. 2014;9(8): e105682.PubMedPubMedCentralCrossRef
31.
Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N, et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0. Eur J Nucl Med Mol Imaging. 2019;46(3):540–57.PubMedCrossRef
32.
Unterrainer M, Vettermann F, Brendel M, Holzgreve A, Lifschitz M, Zahringer M, et al. Towards standardization of 18F-FET PET imaging: do we need a consistent method of background activity assessment? EJNMMI Res. 2017;7(1):48.PubMedPubMedCentralCrossRef
33.
Krokos G, Pike LC, Cook GJR, Marsden PK. Standardisation of conventional and advanced iterative reconstruction methods for Gallium-68 multi-centre PET-CT trials. EJNMMI Phys. 2021;8(1):52.PubMedPubMedCentralCrossRef
34.
Texte E, Gouel P, Thureau S, Lequesne J, Barres B, Edet-Sanson A, et al. Impact of the Bayesian penalized likelihood algorithm (Q.Clear®) in comparison with the OSEM reconstruction on low contrast PET hypoxic images. EJNMMI Phys. 2020;7(1):28.PubMedPubMedCentralCrossRef
35.
Alkhaibary A, Alassiri AH, AlSufiani F, Alharbi MA. Ki-67 labeling index in glioblastoma; does it really matter? Hematol Oncol Stem Cell Ther. 2019;12(2):82–8.PubMedCrossRef
36.
Armocida D, Frati A, Salvati M, Santoro A, Pesce A. Is Ki-67 index overexpression in IDH wild type glioblastoma a predictor of shorter progression free survival? A clinical and Molecular analytic investigation. Clin Neurol Neurosurg. 2020;198: 106126.PubMedCrossRef
37.
Johannessen AL, Torp SH. The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol Oncol Res. 2006;12(3):143–7.PubMedCrossRef
38.
Zeng A, Hu Q, Liu Y, Wang Z, Cui X, Li R, et al. IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma. Oncotarget. 2015;6(30):30232–8.PubMedPubMedCentralCrossRef
39.
Miyake K, Shinomiya A, Okada M, Hatakeyama T, Kawai N, Tamiya T. Usefulness of FDG, MET and FLT-PET studies for the management of human gliomas. J Biomed Biotechnol. 2012;2012: 205818.PubMedPubMedCentralCrossRef
40.
Cicuendez M, Lorenzo-Bosquet C, Cuberas-Borros G, Martinez-Ricarte F, Cordero E, Martinez-Saez E, et al. Role of [11C] methionine positron emission tomography in the diagnosis and prediction of survival in brain tumours. Clin Neurol Neurosurg. 2015;139:328–33.PubMedCrossRef
41.
Saito T, Maruyama T, Muragaki Y, Tanaka M, Nitta M, Shinoda J, et al. 11C-methionine uptake correlates with combined 1p and 19q loss of heterozygosity in oligodendroglial tumors. AJNR Am J Neuroradiol. 2013;34(1):85–91.PubMedPubMedCentralCrossRef
42.
Laudicella R, Albano D, Alongi P, Argiroffi G, Bauckneht M, Baldari S, et al. 18F-Facbc in prostate cancer: a systematic review and meta-analysis. Cancers (Basel). 2019;11(9):1348.PubMedPubMedCentralCrossRef
43.
Parent EE, Benayoun M, Ibeanu I, Olson JJ, Hadjipanayis CG, Brat DJ, et al. [18F]Fluciclovine PET discrimination between high- and low-grade gliomas. EJNMMI Res. 2018;8(1):67.PubMedPubMedCentralCrossRef
44.
Tsuyuguchi N, Terakawa Y, Uda T, Nakajo K, Kanemura Y. Diagnosis of brain tumors using amino acid transport PET imaging with 18F-fluciclovine: a comparative study with L-methyl-11C-methionine PET imaging. Asia Ocean J Nucl Med Biol. 2017;5(2):85–94.PubMedPubMedCentral
Metadata
Title
Impact of [11C]methionine PET with Bayesian penalized likelihood reconstruction on glioma grades based on new WHO 2021 classification
Authors
Kei Wagatsuma
Kensuke Ikemoto
Motoki Inaji
Yuto Kamitaka
Shoko Hara
Kaoru Tamura
Kenta Miwa
Kaede Tsuzura
Taisei Tsuruki
Noriaki Miyaji
Kenji Ishibashi
Kenji Ishii
Publication date
11-03-2024
Publisher
Springer Nature Singapore
Published in
Annals of Nuclear Medicine / Issue 5/2024
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-024-01911-x

Other articles of this Issue 5/2024

Annals of Nuclear Medicine 5/2024 Go to the issue

Original Article

The active papillary muscle sign in 18F-FDG PET/CT cardiac sarcoidosis exams and its relationship with myocardial suppression

Original Article

Improvement in the estimation of perfusable tissue fraction and myocardial flow reserve in the ischemic myocardial lesions using ECG-gated dynamic myocardial PET with 15O-water

Original Article

Properties of [18F]FAPI monitoring of acute radiation pneumonia versus [18F]FDG in mouse models

Original Article

A fully automatic deep learning-based method for segmenting regions of interest and predicting renal function in pediatric dynamic renal scintigraphy

Special Article

Manual on the proper use of the 211At-labeled PSMA ligand ([211At]PSMA-5) for clinical trials of targeted alpha therapy (1st edition)

Original Article

Effect of Cyclosporin H on ischemic injury and neutrophil infiltration in cerebral infarct model of rats via PET imaging